Work

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

Year: 2015

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(15)60159-3

Authors: Christophe Hézode, Tarik Asselah, K Rajender Reddy, Tarek Hassanein, Marina Berenguer, Katarzyna Fleischer-Stepniewska, Patrick Marcellin, Coleen Hall, Gretja Schnell, Tami Pilot-Matias, Niloufar Mobashery, Rebecca Redman, Regis A Vilchez, Stanislas Pol

Institutions: Inserm, Université Paris-Est Créteil, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, Hôpital Beaujon, Centre de Recherche sur l'Inflammation, Université Paris Diderot, University of Pennsylvania, Universitat de València, Hospital Universitari i Politècnic La Fe, Wroclaw Medical University, AbbVie (United States), Institut Pasteur, Université Paris Descartes

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: AbbVie

OpenAlex ID: W2069465518

FWCI: 34.32

Cites: 29

Cited by: 261

Related to: 10